My Cart
You have no items in your shopping cart.
Ship in Europe, Find out rates!
Language
Arvenum 500mg 60 Coated Tablets
Regular Price
€29.80
Special Price
€27.29
-8%
Save: €2.51
In stock
Recent lowest price:
€26.59
- box Delivery in Italy in 24/48 and free returns
- star3.000+ positive reviews
- dropboxOver 60,000 products in the catalog
Manufacturer
STRODER
SKU
024552046
Active principle
DIOSMINA/ESPERIDINA
NAME
ARVENUM 500 MG TABLETS COATED WITH FILM
PHARMACOTHERAPEUTIC CATEGORY
Vasoprotector and venotonic.
ACTIVE PRINCIPLES
Purified flavonoic fraction, micronized 500 mg consisting of: diosmin 450 mg; flavonoids expressed in hesperidin 50 mg.
EXCIPIENTS
Sodium carboxymethyl starch, microcrystalline cellulose, gelatin, glycerin, hypromellose, sodium lauryl sulfate, yellow iron oxide E 172, red iron oxide E 172, titanium dioxide, macrogol 6000, magnesium stearate, talc.
INDICATIONS
Symptoms attributable to venous insufficiency; states of capillary fragility.
CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity 'to the active substance or to any of the excipients.
DOSAGE
2 film-coated tablets per day (1 at noon and 1 in the evening) at mealtimes, even in venous insufficiency of the haemorrhoidal plexus.
STORAGE
This medicinal product does not require any special storage conditions.
WARNINGS
None.
INTERACTIONS
No interaction studies have been performed.
SIDE EFFECTS
The following adverse effects or reactions have been reported and classified according to the following frequency: very common (> = 1/10); common (> = 1/100, <1/10); uncommon (> = 1 / 1,000, <1/100); rare (> = 1 / 10,000, <1 / 1,000); very rare (<1 / 10,000), not known. Nervous system disorders. Rare: dizziness, headache, malaise Gastrointestinal disorders; common: diarrhea, dyspepsia, nausea, vomiting; uncommon: colitis; not known: abdominal pain. Skin and subcutaneous tissue disorders. Rare: rash, itching, hives; not known: edema of the face, lips, eyelid; Quincke's edema. Disorders of the blood and lymphatic system. Not known: thrombocytopenia. The reporting of suspected adverse reactions that occur after the authorization of the drug is important, as it allows continuous monitoring of the risk / benefit ratio of the drug.
PREGNANCY AND BREASTFEEDING
The safety of the drug in pregnancy has not been determined, therefore it is advisable not to administer the product during pregnancy. In the absence of data on excretion in milk, treatment should be avoided during lactation.
ARVENUM 500 MG TABLETS COATED WITH FILM
PHARMACOTHERAPEUTIC CATEGORY
Vasoprotector and venotonic.
ACTIVE PRINCIPLES
Purified flavonoic fraction, micronized 500 mg consisting of: diosmin 450 mg; flavonoids expressed in hesperidin 50 mg.
EXCIPIENTS
Sodium carboxymethyl starch, microcrystalline cellulose, gelatin, glycerin, hypromellose, sodium lauryl sulfate, yellow iron oxide E 172, red iron oxide E 172, titanium dioxide, macrogol 6000, magnesium stearate, talc.
INDICATIONS
Symptoms attributable to venous insufficiency; states of capillary fragility.
CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity 'to the active substance or to any of the excipients.
DOSAGE
2 film-coated tablets per day (1 at noon and 1 in the evening) at mealtimes, even in venous insufficiency of the haemorrhoidal plexus.
STORAGE
This medicinal product does not require any special storage conditions.
WARNINGS
None.
INTERACTIONS
No interaction studies have been performed.
SIDE EFFECTS
The following adverse effects or reactions have been reported and classified according to the following frequency: very common (> = 1/10); common (> = 1/100, <1/10); uncommon (> = 1 / 1,000, <1/100); rare (> = 1 / 10,000, <1 / 1,000); very rare (<1 / 10,000), not known. Nervous system disorders. Rare: dizziness, headache, malaise Gastrointestinal disorders; common: diarrhea, dyspepsia, nausea, vomiting; uncommon: colitis; not known: abdominal pain. Skin and subcutaneous tissue disorders. Rare: rash, itching, hives; not known: edema of the face, lips, eyelid; Quincke's edema. Disorders of the blood and lymphatic system. Not known: thrombocytopenia. The reporting of suspected adverse reactions that occur after the authorization of the drug is important, as it allows continuous monitoring of the risk / benefit ratio of the drug.
PREGNANCY AND BREASTFEEDING
The safety of the drug in pregnancy has not been determined, therefore it is advisable not to administer the product during pregnancy. In the absence of data on excretion in milk, treatment should be avoided during lactation.